Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

17.40 +0.70 (+4.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 185,251
Open 16.69
Bid (Size) 16.40 (200)
Ask (Size) 17.80 (4,900)
Prev. Close 16.70
Today's Range 16.69 - 17.65
52wk Range 11.09 - 23.00
Shares Outstanding 25,688,062
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+7.0%
+7.0%
1 Month
+17.5%
+17.5%
3 Month
+6.4%
+6.4%
6 Month
-2.5%
-2.5%
1 Year
+27.1%
+27.1%

More News

Read More
News headline image
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
A Look Ahead: Eton Pharmaceuticals's Earnings Forecast ↗
Via Benzinga
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharma (ETON) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
ETON PHARMACEUTICALS INC (NASDAQ:ETON) Reports Q3 2025 Revenue Beat and EPS Miss ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton (ETON) Q2 Revenue Jumps 108% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue ↗
Via Benzinga
News headline image
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts ↗
Via Benzinga
News headline image
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Earnings Scheduled For May 13, 2025 ↗
Via Benzinga
News headline image
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Eton Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Eton Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Eton Pharmaceuticals, Inc. - Common Stock trade on?
Eton Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Eton Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Eton Pharmaceuticals, Inc. - Common Stock is ETON on the Nasdaq Stock Market
What is the current price of Eton Pharmaceuticals, Inc. - Common Stock?
The current price of Eton Pharmaceuticals, Inc. - Common Stock is 17.40
When was Eton Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Eton Pharmaceuticals, Inc. - Common Stock was at 03/10/26 04:00 PM ET
What is the market capitalization of Eton Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Eton Pharmaceuticals, Inc. - Common Stock is 446.97M
How many shares of Eton Pharmaceuticals, Inc. - Common Stock are outstanding?
Eton Pharmaceuticals, Inc. - Common Stock has 447M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.